<DOC>
	<DOCNO>NCT00144911</DOCNO>
	<brief_summary>This study evaluate effect two medicine COPD ( Chronic Obstructive Pulmonary Disease ) exacerbation . This study last 56 week , subject visit clinic 10 time . Subjects give breathe test record breathing symptom daily diary card . All study relate medicine medical examination provide cost . The two drug use study approve FDA use patient COPD .</brief_summary>
	<brief_title>ADVAIR® DISKUS® Inhaler ( Fluticasone Propionate/Salmeterol ) Versus SEREVENT® DISKUS® Inhaler ( Salmeterol ) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations . ADVAIR® DISKUS® Inhaler SEREVENT® DISKUS® Inhaler Are Trademarks GSK Group Companies .</brief_title>
	<detailed_description>A Randomized , Double-Blind , Parallel Group , 52-week Study Compare Effect Fluticasone Propionate/Salmeterol DISKUS® inhaler Combination Product 250/50mcg twice daily ( BID ) Salmeterol DISKUS® inhaler 50mcg BID Annual Rate Moderate/Severe Exacerbations Subjects Chronic Obstructive Pulmonary Disease ( COPD )</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Diagnosis COPD ( chronic obstructive pulmonary disease ) . Current previous cigarette smoker smoke history least 10 packyears . History least 1 COPD exacerbation 12 month prior screen . Forced expiratory volume one second ( FEV1 ) less equal 50 % predict normal . Current diagnosis asthma . Additional respiratory disorder COPD ( eg , sarcoidosis , alpha1 antitrypsin deficiency , cystic fibrosis , active tuberculosis ) . Concurrent use longacting betaagonists , longacting anticholinergic , inhaled oral corticosteroid , theophylline , investigational medication , ritonavir , antileukotrienes . Lung resection surgery within 1 year screening . Abnormal clinically significant ECG finding screen . Other inclusion exclusion criterion evaluate first study visit .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>exacerbation</keyword>
	<keyword>breathing</keyword>
	<keyword>chronic obstructive pulmonary disease</keyword>
</DOC>